Warning Letter — Fareva Amboise
The FDA's Center for Veterinary Medicine issued a warning letter to Fareva Amboise following an inspection that identified deviations from Current Good Manufacturing Practice (CGMP) regulations.
This affects Fareva Amboise, specifically their veterinary medicine manufacturing operations, quality control units, and regulatory compliance departments.
A Warning Letter from the CVM suggests significant compliance lapses that could lead to regulatory action if not remediated. For contract manufacturers, this may impact their ability to support client applications or maintain production timelines for veterinary products until the FDA verifies corrective actions.
Quality teams at contract manufacturing sites should review internal audit findings against CVM standards. RA and QA leadership must ensure that facility responses address the underlying root causes cited in the warning letter rather than just immediate corrections.
FDA Warning Letter issued to: Fareva Amboise. 04/10/2026 — Center for Veterinary Medicine. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/fareva-amboise-723502-04102026
Open in openFDA / FDA.gov